Stockscreener 앱 받기
11.45
5.72%
0.62
시장 영업 전:
11.67
0.22
+1.92%
Polyrizon Ltd 주식(PLRZ)의 최신 뉴스
Polyrizon Launches Key Human Study to Advance NASARIX Allergy Blocker Toward FDA Pathway - TipRanks
Polyrizon (PLRZ) launches NASARIX™ human study to assess nasal residence and aid FDA path - Stock Titan
Polyrizon stock surges on human study for allergy blocker By Investing.com - Investing.com South Africa
Polyrizon Ltd. Enters Agreement With European University Medical Center And Clinical Research Organization For Human Study Of NASARIX? - marketscreener.com
Polyrizon initiates nasal residence time study for allergy blocker - Investing.com
Polyrizon initiates nasal residence time study for allergy blocker By Investing.com - Investing.com Canada
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway - The Manila Times
How long can a nasal allergy blocker stay put? New human study aims to find out - Stock Titan
Polyrizon Wins European Patent Publication for Mucoadhesive Nasal Drug Delivery Platform - TipRanks
Polyrizon (Nasdaq: PLRZ) moves ahead on European nasal drug patent - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon Marches on European Patent - Baystreet.ca
Polyrizon receives European patent application publication - Investing.com
Polyrizon receives European patent application publication By Investing.com - Investing.com India
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology - The Manila Times
Polyrizon Ltd. Announces Publication of European Patent Application for Innovative Nasal Drug Delivery Technology - Quiver Quantitative
Polyrizon Sets July 13, 2026 AGM to Vote on Board, Pay and Auditor Mandates - The Globe and Mail
Polyrizon schedules annual shareholder meeting for July 13 By Investing.com - Investing.com Canada
Polyrizon Secures Three Key U.S. Sites for NASARIX Allergy Trial - TipRanks
Polyrizon schedules annual shareholder meeting for July 13 - Investing.com
Polyrizon (PLRZ) 2026 AGM to vote on compensation policy, major RSU grants and Deloitte re-appointment - Stock Titan
Polyrizon (Nasdaq: PLRZ) signs 3 key U.S. sites for NASARIX allergy trial - Stock Titan
Polyrizon signs two more U.S. sites for allergy trial By Investing.com - Investing.com South Africa
Polyrizon signs two more U.S. sites for allergy trial - Investing.com
Polyrizon Ltd. Expands Clinical Trial Network for NASARIX™ Allergy Blocker with Two New U.S. Sites - Quiver Quantitative
New nasal gel trial to block airborne seasonal allergens in U.S. - Stock Titan
Polyrizon extends exclusivity for 51% Arrow Aviation acquisition - scanx.trade
Polyrizon extends exclusivity period for Arrow Aviation acquisition talks By Investing.com - Investing.com Nigeria
Polyrizon Extends Exclusivity on Proposed 51% Acquisition of Arrow Aviation - TipRanks
Polyrizon extends exclusivity period for Arrow Aviation acquisition talks - Investing.com
Polyrizon (NASDAQ: PLRZ) prolongs Arrow Aviation 51% stake talks - Stock Titan
Polyrizon Shares Flat After Delay in New Filing Near Highs - Bez Kabli
Polyrizon Appoints Veteran Entrepreneur Ami Oren to Board of Directors - The Globe and Mail
Polyrizon Ltd. (PLRZ) Posts Modest Gain as Stock Consolidates Near Support LevelsETH Profile - The Legal Advocate
Polyrizon (PLRZ) appoints entrepreneur Ami Oren as new Class I director - Stock Titan
Polyrizon Ltd. (PLRZ) Soars Over 20%: Key Levels and Potential ScenariosBollinger Squeeze - The Legal Advocate
Polyrizon Ltd. (PLRZ) Surges Over 20% — Key Resistance Level in FocusOpen Trading Community - Newser
PLRZ Technical Analysis | Trend, Signals & Chart Patterns | POLYRIZON LTD (NASDAQ:PLRZ) - ChartMill
Number of shareholders of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Polyrizon signs clinical trial agreement with clinical research site for Nasarix - TipRanks
Polyrizon signs first clinical trial agreement for allergy drug By Investing.com - Investing.com India
Polyrizon Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Trial - geneonline.com
Polyrizon signs first clinical trial agreement for allergy drug - Investing.com
Polyrizon Secures First U.S. Clinical Site for NASARIX Allergy Blocker Trial - TipRanks
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial - The Manila Times
Polyrizon Ltd. Signs Clinical Trial Agreement for NASARIXTM Allergy Blocker Study in Texas - Quiver Quantitative
Polyrizon (Nasdaq: PLRZ) signs first U.S. clinical site for NASARIX PL-14 allergy study - Stock Titan
Nasal spray to block airborne allergens heads to first U.S. allergy trial site - Stock Titan
TradingKey - TradingKey
Polyrizon develops nasal barrier tech to block multiple respiratory viruses amid rising viral threats - Pluang
Nasal barrier tech: how Polyrizon wants to plug gaps before vaccines - Stock Titan
The growth trajectory Polyrizon (PLRZ) is on and where it leads (+15.56%) 2026-05-08Macro Trends - newser.com
1.27%
1.43%
자본화:
|
볼륨(24시간):